 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kodiak Sciences Inc. (NASDAQ:KOD  Get Free Report) has earned a consensus recommendation of Reduce from the seven brokerages that are covering the firm, MarketBeat Ratings...

Brokerages Set Kodiak Sciences Inc. (NASDAQ:KOD) PT at $7.33

Kodiak Sciences Inc. (NASDAQ:KOD  Get Free Report) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 2,710,000 shares, a growth...

Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Up 14.3% in August

Shares of Kodiak Sciences Inc. (NASDAQ:KOD  Get Free Report) have been assigned a consensus rating of Reduce from the seven ratings firms that are currently covering the firm...

Kodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Recommendation of "Reduce" from Brokerages

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference PR Newswire PALO...

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein...

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Russell Investments Group Ltd. boosted its position in Kodiak Sciences Inc. (NASDAQ:KOD  Free Report) by 2,907.1% during the first quarter, according to its most recent disclosure with the...

Russell Investments Group Ltd. Grows Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Kodiak Sciences Inc. (NASDAQ:KOD  Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling...

Short Interest in Kodiak Sciences Inc. (NASDAQ:KOD) Increases By 8.7%

Kodiak Sciences Inc. (NASDAQ:KOD Get Free Report) has earned an average recommendation of Reduce from the seven brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have issued a hold rating on the company. The average 12-...

Kodiak Sciences Inc. (NASDAQ:KOD) Given Consensus Recommendation of "Reduce" by Brokerages

Shares of Kodiak Sciences Inc. (NASDAQ:KOD  Get Free Report) have earned an average recommendation of Reduce from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and ...

Kodiak Sciences Inc. (NASDAQ:KOD Free Report) Research analysts at Chardan Capital dropped their FY2023 earnings estimates for Kodiak Sciences in a report issued on Tuesday, August 15th. Chardan Capital analyst D. Gataulin now expects that the company will post earnings per share of ($3.66) for the ...

FY2023 Earnings Estimate for Kodiak Sciences Inc. (NASDAQ:KOD) Issued By Chardan Capital

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Watchers	3,614
52-Wk Low	$1.95
52-Wk High	$9.80

Market Cap	$102.28M
Volume (M)	483,607.00
52-Wk High	$9.80
52-Wk Low	$1.95

KOD Kodiak Sciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals